Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠

Program Overview

The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagganath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.

Credit Expired

Target Audience

Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
  • Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
  • Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM

Activity Faculty


Sundar Jagannath, MD, FASCO

Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY


James Hoffman, MD

Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL


María-Victoria Mateos, MD, PhD

Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources